Login to Your Account



Other News To Note


Monday, September 19, 2011
Cempra Pharmaceuticals Inc., of Chapel Hill, N.C., presented abstracts showing that its antibiotic candidate CEM-101 can be given intravenously without pain in a rabbit ear vein model and provide evidence that inhibition of nicotinic acetylcholine receptors may account for some adverse events associated with telithromycin.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription